Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer

Laboratory Investigation

Volumn 81, Issue 2, 2001, Pages 217-229

  Burri, Nathalie ^a   Shaw, Phillip ^a   Bouzourene, Hanifa ^a   Sordat, Isabelle ^b   Sordat, Bernard ^b   Gillet, Michel ^c   Schorderet, Daniel ^c   Bosman, Fred T ^a   Chaubert, Pascal ^a  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; PROTEIN MDM2; PROTEIN P14; PROTEIN P16; UNCLASSIFIED DRUG; CARRIER PROTEIN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PRIMER DNA; PROTEIN; PROTEIN P14ARF; PROTEIN P16INK4A; TUMOR PROTEIN;

ADENOCARCINOMA; ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL NUCLEUS; CLINICAL ARTICLE; COLON CANCER; EXON; FEMALE; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METHYLATION; PRIORITY JOURNAL; CELL CULTURE; COLON; COLON TUMOR; CYTOLOGY; DNA METHYLATION; GENE SILENCING; GENETICS; INTESTINE MUCOSA; MUTATION; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

CARRIER PROTEINS; COLON; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA PRIMERS; EXONS; GENE SILENCING; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; INTESTINAL MUCOSA; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS); PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0034745679     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780230     Document Type: Article

References (54)

1. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
2. p53 represses Sp1 DNA binding and HIV-LTR directed transcription
3. INK4a(MTS1) in B-cell and T-cell lymphomas
4. Sp1 methylation protects a CpG island from de novo methylation
5. Complex methylation patterns analyzed by single-strand conformation polymorphism
6. Rates of p16(MTS1) mutation in primary tumors with 9p loss
7. An improved method for rapid screening of DNA mutation by nonradioactive single-strand conformation polymorphism procedure
8. K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis
9. INK4 (MTS1) gene inactivation in testicular germ cell tumors
10. Single step method of RNA isolation by acid guanidium thiocyanate-phenolchlorophorm extraction
11. High sensitivity mapping of methylated cytosines
12. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia
13. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers
14. WAF1, a potential mediator of p53 tumor suppression
15. INK4a methylation and p53 mutational status
16. A genetic model for colorectal tumorigenesis
17. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands
18. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed tissues correlates with gene silencing
19. Mdm2 promotes the rapid degradation of p53
20. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
21. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant methylation in all common human cancers
22. A cell cycle regulator potentially involved in genesis of many tumor types
23. Tumor spectrum in ARF-deficient mice
24. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
25. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19 ARF
26. ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts
27. DNA methylation differences associated with tumor tissues identified by genome scanning analysis
28. Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island
29. INK4A transcript
30. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia
31. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancer
32. ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo
33. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation
34. ink4A alleles in neoplasia
35. Mutation and altered expression of p16INK4 in human cancer
36. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53
37. Signaling to p53: Breaking the MDM2-p53 circuit
38. Cancer associated mutations at the INK4a locus cancel cell cycle arrest by p16 INK4a but not by the alternative reading frame protein p19ARF
39. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
40. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wildtype p53
41. The p16INK4a/CDKN2A tumor suppressor and its relatives
42. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4
43. Role of the INK4a locus in tumor suppression and cell mortality
44. Cancer cell cycles
45. Tumor surveillance via the ARF-p53 pathway
46. p16 gene in uncultured tumors
47. Extensive methylation spanning the Rb promoter in retinoblastoma tumors
48. Complex structure and regulation of the p16 (MST1) locus
49. ARF, participates in a regulatory feedback loop with p53 and MDM2
50. CpG island methylator phenotype in colorectal cancer
51. Cooperative signals governing ARF-Mdm2 interaction and nucleolar localization of the complex
52. The retinoblastoma protein and cell cycle control
53. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53
54. ARF-INK4a locus deletion impairs both the RB and p53 tumor suppression pathways